- The EIB has signed an €18 million venture debt deal with Belgian biotech company Novadip funding innovation on its therapies for rare bone-related genetic diseases.
- Novadip will further develop its unique bone tissue regeneration platform to create new solutions for patients with limited or no effective treatment options.
- The agreements were made possible with the support of the InvestEU Programme, which aims to trigger more than €372 billion in additional investment between 2021 and 2027.
Belgium: InvestEU – EIB venture debt for bone therapy innovator Novadip